Business
BullFrog AI Announces Three-Year Global Strategic Partnership with the Lieber Institute for Brain Development
The Strategic Collaboration will Leverage BullFrog AI's bfLEAP™ AI Platform to Accelerate R&D Initiatives, Including New Drug Target and Disease
About this update from Bullfrog Ai Holdings, Inc.
[{"type":"text","content":"The Strategic Collaboration will Leverage BullFrog AI's bfLEAP™ AI Platform to Accelerate R&D Initiatives, Including New Drug Target and Disease Biomarker Identification\nGAITHERSBURG, Md., Sept. 13, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) (\"BullFrog AI\" or the \"Company\"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced a three-year global strategic partnership with the Lieber Institute for Brain Development (LIBD), a non-profit research institute that maintains the world's largest repository of postmortem brains for the study of neuropsychiatric disorders. Under the terms of the agreement, BullFrog AI will leverage its bfLEAP™ platform to mine LIBD's comprehensive brain data, including transcriptomic, genomic, DNA methylation, cell-line, clinical, and imaging data. The goal of the partnership is to identify previously unrecognized relationships between genes and pathways in the brain and the development of neurologic and psychiatric disorders, thereby facilitating the development of more effective treatments for diseases of the human brain. The collaboration will proceed in two stages, with the first involving unsupervised construction of graphical models to reveal relationships between brain diseases and genomic/biologic attributes, with the goal of identifying new biomarkers and drug targets across disorders. The second stage will involve creating disease-specific models that will enable identification of genes and pathways within these respective disorders. “This first of its kind global partnership with LIBD represents a significant advancement in using AI to drive precision medicine and will leverage BullFrog AI's bfLEAP™ artificial intelligence platform to accelerate research and development initiatives, including drug repurposing, clinical trial optimization, and drug target identification,\" said Vin Singh, CEO of BullFrog AI. \"Access to best-in-class data is a critical first step in harnessing AI to improve drug development. Combining our proprietary bfLEAP™ artificial intelligence platform with LIBD’s extensive brain-related data positions us to accelerate the development of therapies for psychiatric and neurologic disorders.” The partne...